BlossomHill reports 45% ORR, 88% DCR for BH-30643 in C797S-positive NSCLC; Phase 2 planned
BlossomHill reported a 45% objective response rate and 88% disease control rate for BH-30643 in EGFR C797S-positive NSCLC.Key Highlights:Original SEC Filing: BlossomHill Therapeutics, Inc. [ BLSM ] - 8-K - Sep. 15, 2026This is an AI-powered summary. It may contain inaccuracies. Consider verifying i…
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.